- $4.83m
- $7.21m
- $3.02m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 0.78 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -70.03% | ||
| Return on Equity | -4273.27% | ||
| Operating Margin | -94.05% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 1.48 | 1.04 | 4.16 | 0.82 | 3.02 | 8.44 | 20.97 | 43.62% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
NAYA Biosciences, Inc. formerly INVO Bioscience, Inc. operates the fertility business, as well as its focus to the development of clinical-stage assets in oncology and autoimmune diseases. The Company’s initial pipeline includes two novel Flex-NK Bispecific Antibodies. NY-303: its GPC3-targeted FLEX-NK Bispecific Antibody for Hepatocellular Carcinoma (HCC). NY-338: its CD38-targeted FLEX-NK Bispecific Antibody for Multiple Myeloma (MM) & Autoimmune Diseases. Its lead GPC3-targeting FLEX-NK bispecific antibody is entering Phase I/II clinical trials and positioned as a monotherapy option to address the unmet needs of the of hepatocellular carcinoma (HCC) patients not responding to standard of care with checkpoint inhibitors. INVOcell is its novel, FDA-cleared and CE-marked intravaginal culture (IVC) device. It offers a viable alternative to vitro fertilization (IVF) that uses the female body for fertilization and incubation, keeping women at the center of the reproductive process.
Directors
- Steven Shum CEO (51)
- Andrea Goren CFO (53)
- Michael Campbell COO (63)
- Barbara Levy SVP
- Britt Carlsson VPR
- Meryle Chamberlain DMK
- Kevin Doody DRC (62)
- Trent Davis IND (53)
- Rebecca Messina IND (49)
- Barbara Ryan IND (61)
- Jeffrey Segal IND (62)
- Matthew Szot IND (46)
- Last Annual
- December 31st, 2023
- Last Interim
- September 30th, 2024
- Incorporated
- July 11th, 2005
- Public Since
- November 11th, 2008
- No. of Shareholders
- 191
- No. of Employees
- 25
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
NASDAQ Capital Market- Shares in Issue
- 4,935,728
- Address
- 5582 Broadcast Court, SARASOTA, 34240
- Web
- https://www.invobioscience.com/
- Phone
- +1 9788789505
- Contact
- Robert Blum
- Auditors
- M&K CPAS, PLLC
Upcoming Events for NAYA
Q4 2024 INVO Bioscience Inc Earnings Release
Q1 2025 INVO Bioscience Inc Earnings Release
Similar to NAYA
Accelerate Diagnostics
NASDAQ Capital Market
Adagio Medical Holdings
NASDAQ Capital Market
Adapthealth
NASDAQ Capital Market
Aethlon Medical
NASDAQ Capital Market
Agape ATP
NASDAQ Capital Market
FAQ
What is the Naya Biosciences share price?
As of Today at 21:13 UTC, shares in Naya Biosciences are trading at $0.98. This share price information is delayed by 15 minutes.
How has the Naya Biosciences share price performed this year?
Shares in Naya Biosciences last closed at $0.98 and the price had moved by -47.66% over the past 365 days. In terms of relative price strength the Naya Biosciences share price has underperformed the S&P500 Index by -59.91% over the past year.
What are the analyst and broker recommendations for Naya Biosciences?
The overall consensus recommendation for Naya Biosciences is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Naya Biosciences dividend yield?
Naya Biosciences does not currently pay a dividend.
Does Naya Biosciences pay a dividend?
Naya Biosciences does not currently pay a dividend.
When does Naya Biosciences next pay dividends?
Naya Biosciences does not currently pay a dividend.
How do I buy Naya Biosciences shares?
To buy shares in Naya Biosciences you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Naya Biosciences?
As of the previous close price of $0.98, shares in Naya Biosciences had a market capitalisation of $4.83m.
Where are Naya Biosciences shares listed?
Here are the trading details for Naya Biosciences:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: NAYA
What kind of share is Naya Biosciences?
Based on an overall assessment of its quality, value and momentum Naya Biosciences is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Naya Biosciences share price forecast for 2024?
The analyst consensus target price for shares in Naya Biosciences is $20.00. That is 1943.32% above the last closing price of $0.98.
Analysts covering Naya Biosciences currently have a consensus Earnings Per Share (EPS) forecast of -$0.20 for the next financial year.
Find out moreWhat is the trend in the Naya Biosciences share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Naya Biosciences. Over the past six months, its share price has outperformed the S&P500 Index by +0.24%.
As of the last closing price of $0.98, shares in Naya Biosciences were trading +9.33% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Naya Biosciences PE Ratio?
The Naya Biosciences PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.98.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Naya Biosciences?
Naya Biosciences' management team is headed by:
- Steven Shum - CEO
- Andrea Goren - CFO
- Michael Campbell - COO
- Barbara Levy - SVP
- Britt Carlsson - VPR
- Meryle Chamberlain - DMK
- Kevin Doody - DRC
- Trent Davis - IND
- Rebecca Messina - IND
- Barbara Ryan - IND
- Jeffrey Segal - IND
- Matthew Szot - IND